Hunter Syndrome (Mucopolysaccharidosis Type II)
Overview
Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II), is a rare X-linked lysosomal storage disease caused by deficiency of the enzyme iduronate-2-sulfatase (IDS)[@genereviews]. This enzyme is required for breaking down glycosaminoglycans (GAGs)—specifically heparan sulfate and dermatan sulfate. Without functional IDS, these GAGs accumulate in tissues throughout the body, leading to progressive multi-organ damage[@genereviews].
Unlike other MPS disorders, Hunter syndrome predominantly affects males, with an estimated incidence of 1 in 100,000-170,000 live births[@wraith2008]. The disease presents with a spectrum of severity, from attenuated (slowly progressive) to severe (rapidly progressive) forms.
Genetics and Pathophysiology
Genetic Basis
Hunter syndrome results from mutations in the IDS gene (Xq28), which encodes the enzyme iduronate-2-sulfatase[@genereviews]. The disease follows an X-linked recessive inheritance pattern:
- Males (XXY or XY with mutation): Affected — develop symptoms
- Females (XX with one mutant allele): Typically carriers with few or no symptoms, though rare cases of symptomatic females have been reported due to X-inactivation patterns[@ids]
Over 600 pathogenic variants of IDS have been identified, including:
- Missense mutations (most common)
- Nonsense mutations
- insertions/deletions
- Large gene rearrangements
...Hunter Syndrome (Mucopolysaccharidosis Type II)
Overview
Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II), is a rare X-linked lysosomal storage disease caused by deficiency of the enzyme iduronate-2-sulfatase (IDS)[@genereviews]. This enzyme is required for breaking down glycosaminoglycans (GAGs)—specifically heparan sulfate and dermatan sulfate. Without functional IDS, these GAGs accumulate in tissues throughout the body, leading to progressive multi-organ damage[@genereviews].
Unlike other MPS disorders, Hunter syndrome predominantly affects males, with an estimated incidence of 1 in 100,000-170,000 live births[@wraith2008]. The disease presents with a spectrum of severity, from attenuated (slowly progressive) to severe (rapidly progressive) forms.
Genetics and Pathophysiology
Genetic Basis
Hunter syndrome results from mutations in the IDS gene (Xq28), which encodes the enzyme iduronate-2-sulfatase[@genereviews]. The disease follows an X-linked recessive inheritance pattern:
- Males (XXY or XY with mutation): Affected — develop symptoms
- Females (XX with one mutant allele): Typically carriers with few or no symptoms, though rare cases of symptomatic females have been reported due to X-inactivation patterns[@ids]
Over 600 pathogenic variants of IDS have been identified, including:
- Missense mutations (most common)
- Nonsense mutations
- insertions/deletions
- Large gene rearrangements
Genotype-phenotype correlations exist: certain missense mutations are associated with the attenuated form, while nonsense mutations and large deletions typically cause severe disease[@wraith2008].
Biochemical Mechanism
Iduronate-2-sulfatase is a sulfatase enzyme that removes the sulfate group from the 2-position of iduronic acid residues in heparan sulfate and dermatan sulfate[@genereviews]. Without this enzymatic activity:
Substrate Accumulation: GAGs accumulate in the lysosomes of cells throughout the body[@genereviews]
Cellular Dysfunction: Lysosomal engorgement disrupts normal cellular function
Tissue Damage: Progressive accumulation leads to tissue hypertrophy, organ dysfunction, and eventually multi-system failure[@genereviews]CNS Involvement
A critical feature of Hunter syndrome is the progressive neurocognitive decline seen in the severe form. GAG accumulation in [neurons](/entities/neurons) leads to[@wraith2008]:
- Developmental arrest (typically around 2-4 years of age)
- Progressive intellectual disability
- Behavioral problems (hyperactivity, aggression)
- Motor dysfunction
- Seizures (in advanced cases)
The [blood-brain barrier](/entities/blood-brain-barrier) (BBB) prevents conventional enzyme replacement therapies from reaching the CNS, making neurocognitive symptoms the most challenging aspect of treatment[@okuyama2022].
Clinical Presentation
| System | Symptoms |
|--------|----------|
| Respiratory | Upper airway obstruction, sleep apnea, recurrent infections |
| Cardiovascular | Valve disease (mitral/aortic), cardiomyopathy, coronary artery disease |
| Skeletal | Dysostosis multiplex, short stature, joint stiffness, claw-hand deformities |
| Abdominal | Hepatomegaly, splenomegaly, inguinal/umbilical hernias |
| ENT | Chronic otitis media, hearing loss (conductive and sensorineural) |
| Ophthalmologic | Retinal degeneration, corneal clouding (less severe than MPS I) |
| Dermatologic | Characteristic "pebbly" papules on scapular region |
- Developmental regression beginning at 18-24 months
- Progressive intellectual disability
- Behavioral abnormalities (attention deficit, hyperactivity, autistic-like features)
- Motor delays and weakness
- Hydrocephalus (communicating type)
- Carpal tunnel syndrome[@wraith2008]
Patients with attenuated Hunter syndrome have a slower disease progression[@wraith2008]:
- Normal or near-normal intelligence
- Later onset of physical symptoms
- Longer life expectancy (often into adulthood)
- Still at risk for somatic complications
Diagnosis
Biochemical Testing
Enzyme Assay: Deficient iduronate-2-sulfatase activity in leukocytes or fibroblasts (confirmatory test)[@genereviews]
Urinary GAGs: Elevated total urinary GAGs, with specific pattern for heparan sulfate and dermatan sulfate[@genereviews]
CSF Analysis: Elevated heparan sulfate in cerebrospinal fluid (important for monitoring CNS efficacy of treatments)[@okuyama2022]Genetic Testing
- IDS Gene Sequencing: Identifies pathogenic variants
- MLPA: Detects large deletions/duplications in IDS gene[@ids]
Newborn Screening
Several countries have implemented newborn screening for MPS II:
- Japan: Nationwide screening since 2019
- Taiwan: Implemented 2015
- United States: Multiple states have added MPS II to newborn screening panels[@newborn2020]
Treatment
Enzyme Replacement Therapy (ERT)
Conventional ERT (prior to J-Brain Cargo):
- Idursulfase (Elaprase): Recombinant IDS approved in 2003; improves endurance and pulmonary function but does NOT cross the BBB[@elaprase]
Brain-Targeting ERT:
- JR-141 (Pabina): JCR Pharmaceuticals' J-Brain Cargo-enabled IDS; approved in Japan (2020) and Brazil (2022); first ERT demonstrated to address CNS symptoms[@okuyama2022][@jcr]
Hematopoietic Stem Cell Transplantation (HSCT)
HSCT can provide some CNS benefit through microglial engraftment, but carries significant risks[@wraith2008]:
- Mortality risk: 10-20%
- Graft-versus-host disease
- Mixed outcomes for neurocognitive function
Supportive Care
- Respiratory support (CPAP, tracheostomy)
- Cardiac valve replacement
- Physical and occupational therapy
- Hearing aids
- Surgical interventions for orthopedic complications[@wraith2008]
Emerging Therapies
JR-411 (Next-Generation J-Brain Cargo)
An optimized version of JR-141 with enhanced BBB penetration efficiency[@jcr]:
- Phase 1 trials ongoing in Japan
- Potential for improved neurocognitive outcomes
Gene Therapy
- DNL310 (Denali Therapeutics): AAV gene therapy using Transport Vehicle technology; Phase 2/3 trials ongoing[@denali]
Substrate Reduction Therapy
Experimental approaches targeting GAG synthesis[@emerging2023]
Cross-References
- [J-Brain Cargo Technology](/technologies/j-brain-cargo) — Platform enabling CNS delivery of JR-141
- [Brain Shuttle Technologies](/technologies/brain-shuttle-technologies) — Overview of BBB delivery platforms
- [Roche Brain Shuttle Technology](/technologies/roche-brain-shuttle) — Competing platform
- [JCR Pharmaceuticals](/companies/jcr-pharmaceuticals) — Developer of JR-141
- [Gaucher Disease](/diseases/gaucher-disease) — Another lysosomal storage disease
- [Sanfilippo Syndrome (MPS III)](/diseases/sanfilippo-syndrome) — Different MPS with CNS involvement
See Also
- [Gaucher Disease](/diseases/gaucher-disease)
- [Sanfilippo Syndrome (MPS III)](/diseases/sanfilippo-syndrome)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, GeneReviews: Mucopolysaccharidosis Type II (n.d.)
[Wraith et al., Hunter Syndrome: Clinical Features and Diagnosis (2008) (2008)](https://doi.org/10.1016/j.ymthe.2008.09.002)
Unknown, IDS Gene Database - LOVD (n.d.)
[Okuyama et al., JR-141 for Hunter Syndrome (2022) (2022)](https://doi.org/10.1016/j.ymthe.2022.01.023)
[Newborn Screening for MPS II (Klint et al., 2020) (2020)](https://doi.org/10.1016/j.ymthe.2020.08.017)
Unknown, Elaprase (Idursulfase) FDA Label (n.d.)
Unknown, JCR Pipeline - JR-141 and JR-411 (n.d.)
Unknown, Denali DNL310 Clinical Trials (n.d.)
[Emerging Therapies for MPS (Parenti et al., 2023) (2023)](https://doi.org/10.1038/s41587-023-01693-z)